Welcome to our dedicated page for Vicarious Surgical news (Ticker: $RBOT), a resource for investors and traders seeking the latest updates and insights on Vicarious Surgical stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vicarious Surgical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vicarious Surgical's position in the market.
Vicarious Surgical Inc. (RBOT) reported its first-quarter 2024 financial results, showcasing a decrease in operating expenses, R&D expenses, general and administrative expenses, and sales and marketing expenses compared to the previous year. The company reported an adjusted net loss of $15.1 million, equating to a loss of $0.09 per share, and a GAAP net loss of $17.0 million, or a net loss per share of $0.10 for the same period. Vicarious Surgical had $84.1 million in cash and investments as of March 31, 2024, with a cash burn rate of $14.1 million for the first quarter. The company reiterated its expected full-year 2024 cash burn of approximately $50 million.
